Browsing Tag
Novartis Pharma AG
5 posts
Can Coartem Baby reshape treatment standards for newborn malaria patients?
Can Coartem Baby reshape neonatal malaria care? Explore what Novartis Pharma AG’s WHO milestone means for global health access and strategy.
What clinicians and regulators will watch next after Itvisma’s positive CHMP opinion
Novartis Pharma AG’s Itvisma gains CHMP backing. Discover what clinicians, regulators, and investors will watch next in SMA gene therapy.
Will multi-year kidney function data secure Vanrafia’s long-term positioning?
Novartis Pharma AG’s ALIGN data test whether eGFR slope preservation can confirm Vanrafia’s clinical benefit. Read the full executive analysis.
GSK to acquire efimosfermin from Boston Pharmaceuticals for $2bn to bolster liver disease pipeline
GSK acquires Phase III-ready efimosfermin from Boston Pharmaceuticals for $2B, expanding its liver disease pipeline with a fibrosis-reversing specialty drug.
Hikma secures exclusive rights to $436M cancer drug in deal with Novugen
Find out how Hikma is strengthening its US oncology portfolio with exclusive rights to a $436M cancer treatment.